Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid

$773m Offer Is Double Current Value

Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.

Vancouver
Zymeworks is headquartered in Vancouver, Canada. • Source: Shutterstock

The management of struggling biotech Zymeworks has rejected a $773m takeover bid from activist investor All Blue Capital, saying the “opportunistic” offer lacks credibility and undervalues the company.

The $10.50 per share cash offer represents more than double the biotech’s current market valuation, which has plunged by nearly...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip